Vertex Pharma (VRTX) Tops Q4 EPS by 26c; Guides FY Revenue
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $557.00 +0.04%
EPS Growth %: 0.0%
Financial Fact:
Net loss attributable to noncontrolling interest (Alios): 696K
Today's EPS Names:
VIVO, PMCB, PLCE, More
EPS Growth %: 0.0%
Financial Fact:
Net loss attributable to noncontrolling interest (Alios): 696K
Today's EPS Names:
VIVO, PMCB, PLCE, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $3.79, $0.26 better than the analyst estimate of $3.53. Revenue for the quarter came in at $2.3 billion versus the consensus estimate of $2.3 billion.
GUIDANCE:
Vertex Pharma sees Q1 2023 revenue of $9.55-9.7 billion, versus the consensus of $9.6 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- John Wiley & Sons, Inc. (WLY) Tops Q1 EPS by 4c ; Offers Guidance
- Lands' End (LE) Tops Q2 EPS by 1c
- Goldman Sachs Adjust Monthly US Director's Cut List
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
